Biomet Introduces First Vitamin E Stabilized Highly Crosslinked Polyethylene Products to the Market
2007年5月12日 - 1:25AM
PRニュース・ワイアー (英語)
WARSAW, Ind., May 11 /PRNewswire-FirstCall/ -- Biomet, Inc.
(NASDAQ:BMET) announced today that Biomet Orthopedics recently
received clearance from the U.S. Food and Drug Administration to
market acetabular hip liners manufactured from E-Poly(TM) Highly
Crosslinked Polyethylene. E- Poly(TM) liners are the world's first
vitamin E stabilized highly crosslinked polyethylene products to be
introduced to the market. Vitamin E, a natural antioxidant, is
expected to improve the longevity of the implant bearings used in
total joint replacements. The E-Poly(TM) material was developed by
combining the research of Massachusetts General Hospital with
Biomet's expertise in polyethylene technology, representing another
innovative first for Biomet Orthopedics. This revolutionary
technology offers multiple benefits for surgeons and patients. In
laboratory testing, E-Poly(TM) liners have demonstrated 95-99% less
wear than the existing low wear rates of Biomet's clinically
successful ArCom(R) polyethylene liners. The E-Poly(TM) material
also provides greater strength when compared to first generation
re-melted highly crosslinked polyethylenes, while maintaining
optimal oxidation resistance. In addition, E-Poly(TM) liners offer
a technologically advanced polyethylene available for use with
large diameter femoral heads, designed to provide a greater degree
of joint stability. The E-Poly(TM) liners will be marketed with
Biomet's broad line of clinically-proven hip stems including the
Taperloc(R) Hip System. The introduction of E-Poly(TM) products is
a testament to Biomet's ongoing commitment to further expand our
product portfolio of improved bearings, which presently includes
ArCom(R), ArComXL(R), M2a-Taper(TM), M2a-Magnum(TM) and
C2a-Taper(TM) technologies. Biomet's President and Chief Executive
Officer Jeffrey R. Binder commented, "We are very pleased to be the
first orthopedic company in the world to market vitamin E
stabilized highly crosslinked polyethylene products. Biomet
continues to lead the market in innovative product introductions
and we are excited to offer these technologically-advanced
polyethylene acetabular liners, the first of our E-Poly(TM)
products." Bench test results are not necessarily indicative of
clinical performance. All trademarks are owned by Biomet
Manufacturing Corp. About Biomet Biomet, Inc. and its subsidiaries
design manufacture and market products used primarily by
musculoskeletal medical specialists in both surgical and
non-surgical therapy. Biomet's product portfolio encompasses
reconstructive products, including orthopedic joint replacement
devices, bone cements and accessories, autologous therapies and
dental reconstructive implants; fixation products, including
electrical bone growth stimulators, internal and external
orthopedic fixation devices, craniomaxillofacial implants and bone
substitute materials; spinal products, including spinal stimulation
devices, spinal hardware and orthobiologics; and other products,
such as arthroscopy products and softgoods and bracing products.
Headquartered in Warsaw, Indiana, Biomet and its subsidiaries
currently distribute products in more than 100 countries.
Forward-Looking Statements This press release contains certain
statements that are "forward-looking statements" within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, as amended. Such statements are
qualified by the inherent risks and uncertainties surrounding
future expectations generally, and also may materially differ from
actual future experience involving any one or more of such
statements. Such risks and uncertainties include our ability to
develop and market new products and technologies in a timely
manner, the effect of the pending merger on Biomet's business and
its relationship with customers, distributors, employees and
suppliers and the risk factors as set forth from time to time in
Biomet's filings with the SEC. The inclusion of a forward-looking
statement herein should not be regarded as a representation by
Biomet that Biomet's objectives will be achieved. Biomet undertakes
no obligation to publicly update forward- looking statements,
whether as a result of new information, future events or otherwise.
For further information contact Greg W. Sasso, Senior Vice
President, Corporate Development and Communications at (574)
372-1528 or Barbara Goslee, Director, Corporate Communications at
(574) 372-1514. DATASOURCE: Biomet, Inc. CONTACT: Greg W. Sasso,
Senior Vice President, Corporate Development and Communications,
+1-574-372-1528, or Barbara Goslee, Director, Corporate
Communications, +1-574-372-1514, both of Biomet, Inc.
Copyright
Biomet (NASDAQ:BMET)
過去 株価チャート
から 8 2024 まで 9 2024
Biomet (NASDAQ:BMET)
過去 株価チャート
から 9 2023 まで 9 2024